CYP2D6 genotypes in Spanish women with breast cancer

被引：26
|
作者：
Ladona, MG
Abildua, RE
Ladero, JM
Roman, JM
Plaza, MA
Agundez, JAG
Munoz, JJ
Benitez, J
机构：
[1] UNIV COMPLUTENSE MADRID, DEPT PHARMACOL, MADRID, SPAIN
[2] UNIV EXTREMADURA, DEPT PHARMACOL, BADAJOZ, SPAIN
[3] SAN CARLOS UNIV HOSP, SERV GASTROENTEROL, MADRID, SPAIN
[4] SAN CARLOS UNIV HOSP, SERV OBSTET & GYNAECOL, BREAST UNIT, MADRID, SPAIN
来源：
CANCER LETTERS | 1996年 / 99卷 / 01期
关键词：
CYP2D6; P4502D6; breast cancer; debrisoquine; polymorphism;
D O I：
10.1016/0304-3835(95)04033-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Wild type and three mutated alleles of the polymorphic CYP2D6 gene were studied in genomic DNA samples from 187 women with breast carcinoma and 151 healthy women by a mutation-specific polymerase chain reaction. The prevalence of the enzyme-inactivating CYP2D6(B) allele was higher among patients (18.2%) than in controls (11.6%; OR = 1.7; 95% c.i. = 1.14-3.13; P = 0.018). This excess was more marked in postmenopausal patients (19.8%, P = 0.0086) and in patients with non-ductal infiltrating carcinomas (25.8%, P = 0.003). The percentage of carriers of only one active gene (heterozygote extensive metabolizers) was higher in patients (31% vs. 19.9%; OR = 1.81; 95% c.i. = 1.06-3.11; P = 0.02). The CYP2D6(B)-carrier state may be related to a greater risk of breast cancer in women.
引用
收藏
页码：23 / 28
页数：6
相关论文
共 50 条
  • [21] CYP2D6*4 allele and breast cancer risk: Is there any association?
    Ana Fernández-Santander
    Miguel del Saz Sánchez
    Armando Tejerina Gómez
    Fernando Bandrés Moya
    Clinical and Translational Oncology, 2012, 14 : 157 - 159
  • [22] Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment
    Ramon y Cajal, T.
    Altes, A.
    Pare, L.
    del Rio, E.
    Alonso, C.
    Barnadas, A.
    Baiget, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (01) : 33 - 38
  • [23] Clinical Implications of CYP2D6 Genotyping in Tamoxifen Treatment for Breast Cancer
    Dezentje, Vincent O.
    Guchelaar, Henk-Jan
    Nortier, Johan W. R.
    van de Velde, Cornelis J. H.
    Gelderblom, Hans
    CLINICAL CANCER RESEARCH, 2009, 15 (01) : 15 - 21
  • [24] CYP2D6*4 allele and breast cancer risk: Is there any association?
    Fernandez-Santander, Ana
    del Saz Sanchez, Miguel
    Tejerina Gomez, Armando
    Bandres Moya, Fernando
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2012, 14 (02) : 157 - 159
  • [25] Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan
    Abduljalil, K.
    Frank, D.
    Gaedigk, A.
    Klaassen, T.
    Tomalik-Scharte, D.
    Jetter, A.
    Jaehde, U.
    Kirchheiner, J.
    Fuhr, U.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (05) : 643 - 651
  • [26] Chinese breast cancer patients with CYP2D6*10 mutant genotypes have a better prognosis with toremifene than with tamoxifen
    Wang, Hongyue
    Ma, Xinchi
    Zhang, Bin
    Zhang, Yaotian
    Han, Ning
    Wei, Linlin
    Sun, Chaonan
    Sun, Shichen
    Zeng, Xue
    Guo, Hong
    Li, Yubing
    Zhang, Yanyu
    Zhao, Jiaming
    Qin, Zilan
    Liu, Zhuang
    Zhang, Na
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (02) : E148 - E153
  • [27] Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen
    Schroth, Werner
    Winter, Stefan
    Muerdter, Thomas
    Schaeffeler, Elke
    Eccles, Diana
    Eccles, Bryony
    Chowbay, Balram
    Khor, Chiea C.
    Tfayli, Arafat
    Zgheib, Nathalie K.
    Eichelbaum, Michel
    Schwab, Matthias
    Brauch, Hiltrud
    FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [28] Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence
    Laurent Azoulay
    Sophie Dell’Aniello
    Laetitia Huiart
    Guillaume Galbaud du Fort
    Samy Suissa
    Breast Cancer Research and Treatment, 2011, 126 : 695 - 703
  • [29] Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence
    Azoulay, Laurent
    Dell'Aniello, Sophie
    Huiart, Laetitia
    du Fort, Guillaume Galbaud
    Suissa, Samy
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 126 (03) : 695 - 703
  • [30] Impact of CYP2D6 Polymorphisms on Tamoxifen Responses of Women with Breast Cancer: A Microarray-based Study in Thailand
    Sukasem, Chonlaphat
    Sirachainan, Ekaphop
    Chamnanphon, Montri
    Pechatanan, Khunthong
    Sirisinha, Thitiya
    Ativitavas, Touch
    Panvichian, Ravat
    Ratanatharathorn, Vorachai
    Trachu, Narumol
    Chantratita, Wasun
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (09) : 4549 - 4553
12345